Finafloxacin

Published
Topics: New Medicines

dm+d

Unassigned

New Medicines

Urinary tract infection

Information

New molecular entity
MerLion
MerLion

Development and Regulatory status

None
Phase II Clinical Trials
None

Category

Quinolones (05.01.12)
A pH-activated fluoroquinolone (optimum pH 5.0 to 6.0). DNA gyrase and DNA topoisomerase IV inhibitor.
Complicated UTIs due to resistant gram-negative bacteria are increasing, mainly due to spread of ESBL-producing bacteria and are usually hospital-acquired. Current treatment options are limited due to resistance of existing antibiotics and a lack of new agents. UTIs are estimated to have the highest incidence of all hospital acquired infections at around 35%, and they are most common in patients aged over 60 years. In 2020/21 there were 123,144 admissions for UTI (therefore cUTIs) in England. [13]
Urinary tract infection
complicated, including acute pyelonephritis, in hospitalised patients
Intravenous